Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”) becomes the first Bangladeshi pharmaceutical company to be approved by the U.S. Food and Drug Administration (US FDA) following successful inspection of its oral solid dosage facility at Tongi, during January 19-22, 2015. The company says it has received the establishment inspection report (EIR) from the US drug regulatory authority stating that the audit is formally concluded. This is a major milestone for the company as well as for the entire industry as this is the first time a Bangladeshi company has received the prestigious FDA approval. This approval is based on the comprehensive audit encompassing all the systems of drug manufacturing: Quality; Facilities and Equipment; Materials; Production; Packaging and Labeling; and Laboratory Controls. Remarkably, there was no 483 observation issued by the US regulatory authority. A 483 form is issued when FDA has observations of non-compliance or deviation from Good Manufacturing Practices (GMP).
Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has become the first Bangladeshi pharmaceutical company to be audited by the US Food and Drug Administration (“FDA”) without any 483 observation. A 483 form is issued when the US FDA has observations of non-compliance or deviation from its current Good Manufacturing Practices (“cGMP”). The inspection of Beximco Pharma’s oral solid dosage manufacturing facility, in Tongi, took place during 19-22 January, 2015.
Country’s leading pharma manufacturer Beximco Pharmaceuticals Ltd makes a foray into Australian Pharma market with the launch of Pantoprazole, a drug for treating gastrointestinal disorder. This is for the first time pharmaceutical product from Bangladesh is being exported to Australia.
Beximco Pharmaceuticals Limited (“BPL” or “Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has received GMP (Good Manufacturing Practices) approval from the Canadian regulatory authority, Health Canada. Beximco Pharma is the first Bangladeshi company to receive GMP accreditation from Health Canada.
The US Ambassador to Bangladesh, His Excellency Dan W. Mozena, visited the state-of-the-art manufacturing facilities of Beximco Pharmaceuticals Ltd. (BPL) at Tongi on November 4, 2014 (Tuesday). He was accompanied by Daniel Keen, Economic Commercial Officer and other officials of the Embassy.
Beximco Pharmaceuticals Limited (“BPL” or “the Company”), the fast-growing manufacturer of generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids, today announces that it has received GMP (“Good Manufacturing Practices”) accreditation from Taiwan Food and Drug Administration (TFDA) as the first Bangladeshi company. The company has received the approval for its oral solid, Inhaler and sterile eye drop facilities.
Mr. Mahbubul Alam, Independent Director of Beximco Pharmaceuticals Ltd., passed away on Friday 6th June, 2014. He had served as a Non-Executive Independent Director of the Company from March 2014. Additionally, he was the Chairman of the Audit Committee.
Mr. Mohammad Abul Qasem, Director of Beximco Pharmaceuticals Ltd., passed away on April 19, 2014 at a local hospital in Dhaka. He was 85. He left behind his wife, three sons and one daughter.
Beximco Pharmaceuticals Limited (“Beximco Pharma”, “BPL” or “the Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, is pleased to announce that Daniel Stewart & Company plc (“Daniel Stewart”) has been appointed as Nominated Adviser to the Company with immediate effect. Daniel Stewart will continue to act as the Company′s Sole Broker.
Beximco Pharmaceuticals Ltd. has won the prestigious Asia's Most Promising Brand award at the Asian Brand & Leadership Summit 2013 held during 26-27 August, 2013 in Dubai. Beximco Pharma ranked among Top 30 from among 200 emerging brands in Asia. It also received Industry's #1 award in pharma category. Beximco Pharma COO Mr. Rabbur Reza received the award at a gala ceremony held on 27 August in Dubai. Company’s Managing Director, Nazmul Hassan MP received the Asia’s Most Influential Leader award for his outstanding leadership and contribution to business and economic growth in the country as well as in the region.